Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study

doi:10.3748/wjg.v30.i27.3304

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3838)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

124

HTML

2783

Figures (1-2)

145

Tables (1-4)

138

Sum=3190

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

128

Download

206

Sum=334

Publishing Process of This Article

Item

Count

Browse

Download

131

Sum=193

Jul 21, 2024 (publication date) through Nov 15, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Jul 21, 2024; 30(27): 3304-3313
Published online Jul 21, 2024. doi: 10.3748/wjg.v30.i27.3304

Table 4 Cost-effectiveness analysis of each regimen

	BQT	VAT-10	VAT-14
Cost (CNY per percent)	334.18	216.80	163.52
Effectiveness (%)	80.90	94.00	93.90
CER (CNY per percent)	4.13	2.31	1.74
ICER (CNY per percent)		-1.82	-2.39

Effectiveness, the eradication rate in the per-protocol analysis (%). VAT: Vonoprazan-amoxicillin dual therapy; BQT: Bismuth quadruple therapy; CER: Cost-effectiveness ratio; Cost: Direct drug costs per patient; ICER: Incremental cost-effectiveness ratio.

Citation: Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, Xu ZK, Chen JX, Chen LH, Lin ZQ, Dai WH, Zhang MQ, Jiang Q, Xiao ZQ, Cheng XX, Zhang XF, You WB, Chen W, Li LQ, Lin WX, Wang YF, Lai FJ, Chen LQ, Huang ZH, Zheng WQ, Wei JQ, Lin ZH. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study. World J Gastroenterol 2024; 30(27): 3304-3313
URL: https://www.wjgnet.com/1007-9327/full/v30/i27/3304.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i27.3304